SELLAS Life Sciences Group, Inc.
SLS
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 cā¦ read more
Healthcare
Biotechnology
17 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$3.86
Price-4.46%
-$0.18
1Y
Price
Market Cap
$406.860m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-33.3%
3y CAGR-46.7%
5y CAGREarnings
-$25.942m
+16.0%
1y CAGR+14.3%
3y CAGR-14.2%
5y CAGREPS
-$0.20
-300.0%
1y CAGR-46.8%
3y CAGR-49.8%
5y CAGRBook Value
$45.630m
$51.555m
Assets$5.925m
Liabilities$599k
DebtDebt to Assets
1.2%
-
Debt to EBITDAFree Cash Flow
-$30.621m
+13.5%
1y CAGR-4.3%
3y CAGR-5.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company